This study tests a new drug, GVV858, for people with certain types of advanced cancer. **Phase I** looks at how safe GVV858 is alone or with other treatments like fulvestrant or letrozole. **Phase II** checks the safety when combined with fulvestrant for breast cancer called HR+/HER2-. HR+ means the cancer grows with hormones, and HER2- means it doesn't have a protein that makes cancer grow faster.
**Key Points:**
- Participants must be 18 or older with advanced cancer, specifically HR+/HER2- breast cancer, or other cancers with certain markers.
- Phase I has no standard therapy available; Phase II requires prior endocrine therapy without prior chemotherapy for advanced disease.
- Study excludes people with heart issues, certain lab test results, or other medical conditions.
Consider joining if you meet the criteria and want to help test this new drug. Remember, there may be risks, and you should discuss with your doctor if this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand